e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
         
Colorado   000-30489   84-1097796
         
(State or other jurisdiction
of incorporation) 		  (Commission File Number)   (IRS Employer Identification No.)
6400 South Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 488-1711
6400 South Fiddler’s Green Circle, Suite 1750, Englewood, CO 80111
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 2.02 Results of Operations and Financial Condition
     On February 13, 2006, Lifeline Therapeutics, Inc. issued a press release entitled “Lifeline Therapeutics, Inc. Announces Q2 FY 2006 Financial and Operating Results.” The press release is attached as Exhibit 99.1 hereto.
Item 7.01 Regulation FD Disclosure
     On February 13, 2006, Lifeline Therapeutics, Inc. issued a press release entitled “Lifeline Therapeutics, Inc. Announces Q2 FY 2006 Financial and Operating Results.” The press release is attached as Exhibit 99.1 hereto.
Item 9.01 Exhibits
     99.1 Press Release, dated February 13, 2006, entitled “Lifeline Therapeutics, Inc. Announces Q2 FY 2006 Financial and Operating Results.”

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: February 13, 2006
         
  LIFELINE THERAPEUTICS, INC.
 		  
  By:   /s/ Gerald J. Houston    
    Gerald J. Houston   
    Chief Financial Officer   

 

 

         
EXHIBIT INDEX
     99.1 Press Release, dated February 13, 2006, entitled “Lifeline Therapeutics, Inc. Announces Q2 FY 2006 Financial and Operating Results.”